ncomplete coronary reperfusion in cases of acute myocardial infarction (AMI) with Thrombolysis In Myocardial Infarction (TIMI) grade I-II results in remote left ventricular (LV) remodeling (ie, enlargement by structural changes) and LV dysfunction compared with TIMI grade III. 1 In cases of successful reperfusion therapy by percutaneous coronary intervention (PCI), however, there are still patients who have large LV volumes and depressed remote LV function after TIMI grade III reflow has been obtained. Such LV enlargement becomes apparent in the remote phase after AMI, whereas it may start much earlier than is generally assumed, occurring within hours of the onset of AMI. 2 For example, the LV end-systolic volume index (LVESVI) has been reported as a strong predictor of adverse outcomes, including mortality, 2 which suggests that the very early LV volume and/or function plays a role in the prognosis of patients with AMI.
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Prediction of remote LV dysfunction and remodeling after AMI has been attempted with several modalities, including myocardial perfusion imaging (MPI). In MPI, using the 99m Tc-labeled myocardial perfusion agent, tracer accumulation in severely ischemic myocardium is reported to eventually recover 7 days after successful reperfusion in patients with AMI. 3 The infarct size as assessed by MPI on the 7 th day is known to be a predictor of remote LV functions and volumes after AMI, 4 but it remains to be determined which of these (LV volumes and/or functions) assessed in the acute phase, perfusion defect size (DS) assessed in the subacute phase of AMI, or both, have predictive value for LV volumes and functions in the remote phase after AMI. The answer may lie in serial assessment of the myocardial perfusion (area at risk or perfusion DS), and LV volumes and functions by MPI combined with quantitative gated SPECT (QGS) in the acute (a few hours after reperfusion), subacute (1 week), and remote (6 months) phases of AMI. Using 16-frame-ECG gating in QGS, an assessment measure of diastolic function, such as a peak filling rate, can also be performed. 5 In the present study, we aimed to assess how the area at risk, the perfusion DS and/or the parameter(s) of LV volumes and functions on the 1 st day and/or 1 week after AMI may predict LV functions and LV enlargement 6 months after AMI with TIMI grade III reperfusion. a prospective study of a series of MPI in 74 patients with sinus rhythm. They were admitted to hospital because of acute ST-elevation myocardial infarction (MI) within 24 h of onset, and were confirmed by emergency cineangiography to have acute coronary occlusion with Rentrop collateral filling grade 6 0-1 (poor collateral flow) before reperfusion. Nine of them were excluded because of TIMI grade 0-II reperfusion after PCI (n=5), previous MI (n=3), or appearance of arrhythmia during the follow up period (n=1). In 17 patients, we could not perform QGS analysis at the 3 time points (tracer administration just before coronary reperfusion, and 1 week and 6 months after AMI) and cineangiographic findings 6 months after AMI. Thus, 48 patients who had TIMI grade III reperfusion obtained by successful PCI were enrolled (Table 1) .
Scintigraphic Study
Patients with acute ST-segment elevation MI who agreed to emergency cardiac catheterization were transferred to the catheter laboratory. Before starting the PCI, 800 MBq of 99m Tc tetrofosmin was administered intravenously while the patient rested (Fig 1) . Coronary reperfusion was performed by PCI using regular balloon angioplasty (10% of 48 patients), coronary bare metal stenting (83%), or directional coronary atherectomy (7%). The grade of residual coronary stenosis at the site of PCI was <50% in all patients. The 1 st MPI was performed in the imaging room adjacent to the catheter laboratory immediately after completing PCI.
The 2 nd and 3 rd MPI was performed 1 week (7±3 days) and 6 months (198±25 days) after PCI for AMI, respectively. At 6 months, the patients were hospitalized for assessment of the presence or absence of coronary restenosis. On these 2 nd and 3 rd MPI, dipyridamole-stress imaging with 400 MBq of 99m Tc tetrofosmin to assess ischemia was performed, followed by imaging at rest with 800 MBq of the same tracer (3 h later).
MPI data acquisition was performed using a low-energy high-resolution collimator connected on-line to Entegra™ (version 2.5.302, GE Medical Systems, Milwaukee, WI, USA). The acquisition consisted of 72 frames at 35 s/frame (5 degrees/step) over a 180-degree arc on a 2-head gamma camera. The short-axis, horizontal long-axis and vertical long-axis images were visually assessed. On the polar map display of Entegra™ using the Emory cardiac Toolbox™ software 7 (version 2.0, Emory Medical Device Group, Atlanta, GA, USA), the defect area (<50% of peak counts) 8 was shown as blacked out, and the size of that area (% of total LV area) was then considered to be the perfusion DS.
On the MPI at rest, 16-frame ECG gating was combined for QGS 9 (version 3.0, QGS Companion, Cedars-Sinai Medical Center, Los Angeles, CA, USA) analysis, and LV end-diastolic volume (LVEDV), LV end-systolic volume (LVESV), and LV ejection fraction (LVEF: reference range 67±10 ml/m 2 ) were calculated. In addition, the peak-filling rate was obtained from the time -volume curve drawn by the p-FAST (version 2. 
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Japan) program. 10 LVEDV and LVESV were corrected for the body surface area of each patient (ie, LVEDV index (LVEDVI): reference range 48±12 ml/m 2 and LVESVI: reference range 17±9 ml/m 2 ). All measurements were performed by an experienced radiologist. The intra-observer variability in the calculation of LVEDV, LVESV and LVEF was 1.3-2.0%.
Pharmaceutical Treatment After AMI
After reperfusion therapy, the standard pharmaceutical therapies shown in Table 1 were started and continued for 6 months in all 48 patients. Each pharmaceutical was administered in a standard dosage range. The 2 nd and 3 rd MPI studies with pharmaceutical stress were started 15 h after taking the last medicines.
Statistical Analysis
The data are expressed as means ± SE. For the following statistical analyses, SPSS program software (SPSS Japan, Tokyo, Japan) was used. One-way ANOVA followed by Bonferroni's post-hoc test was performed for multiple comparisons. For assessment of the qualitative parameters (gender, coronary risk factors, number of diseased vessels etc), a chi-square analysis was performed. To assess the significant predictors for LV volumes and functions 6 months after AMI (the explained variable), we considered all 10 scintigraphic parameters available (perfusion DS, LVEDVI, LVESVI, LVEF, peak-filling rate on the 1 st day and 1 week after AMI) and LV peak systolic and end-diastolic pressures measured by cardiac catheterization on the 1 st day of AMI (Table 1) , as candidates for the explanatory variables.
Based on these results, we then performed forward stepwise linear regression analyses. The 1 st explanatory value was that which gave the maximal F value. Each subsequent variable was then adopted to give the maximal F value as long as it was significant (<0.05). We further performed linear regression analyses using each parameter alone. For strict comparisons of the coefficient of determination of the regression formulas with a different number of explanatory variables, we calculated the coefficient of determination adjusted for the degree of freedom (R* 2 ). In addition, Akaike's information criterion (AIC) 11 was calculated for the same purpose, to reinforce the statistical conclusion on these comparisons; the lowest AIC value indicates the best-fitting regression formula among those with a different number of explanatory variables. We used an unpaired t-test for the assessment of the possible influence of the reperfusion method or pharmaceutical treatment on LV remodeling, or of the incidence of coronary restenosis on LV remodeling.
Results

Clinical Course During Hospitalization and After Discharge
Mean LV peak systolic and end-diastolic pressures on the 1 st day of MI were 125±3 and 17±1 mmHg, respectively. The measures on the 1 st MPI were performed 36±2 min after the time of reperfusion. There were no major cardiac events (ie, death, hospitalization because of cardiac events, or new anginal attacks) in any patients during the course of this study.
Cineangiographic Findings in the Remote Phase
Cineangiography 6 months after AMI revealed 5 patients (10%) with coronary restenosis (grade of coronary stenosis ≥50%) at the site of PCI, but there were no de novo coronary lesions (grade of coronary stenosis ≥50%) during the 6-month observation period. 
Changes in LV Volumes and Function After AMI
The area at risk (perfusion defect area on the 1 st day of AMI) was 40±2% of the total LV area. The perfusion DS decreased at 1 week, and further at 6 months after AMI compared with that on the 1 st day (p<0.05 each, Fig 2) . At 1 week after AMI, the myocardial area salvaged (calculated by the area at risk minus perfusion DS at 1 week), that is, 27±3% of the area at risk, was 10±1% of the total LV area. LVEDVI and LVESVI decreased 6 months after AMI compared with the values obtained on the 1 st day (p<0.05 each, Fig 3) . LVEF increased 6 months after AMI compared with 1 day or 1 week after AMI (p<0.05), but the peakfilling rate did not change (Fig 4) . The serial changes in the perfusion DS and LV volumes in each patient (Figs 2,3) show the trend that the patients who had a large perfusion defect or large LV volumes 6 months after AMI had larger corresponding values on the 1 st day of AMI.
Predictors of LV Volumes and Functions 6 Months After AMI
The results of the multiple linear regression analyses in predicting remote LV function and structure are shown in Table 2 . The perfusion DS at 6 months after AMI was best expressed by using the size at 1 week after AMI, whereas LVEDVI, LVESVI, and LVEF at 6 months after AMI were not predicted from the data either on the 1 st day after AMI or 1 week after AMI alone, better than their combination, as shown in the 2 nd and 3 rd lines of each item. Thus, among the formulas, the highest R* 2 and the lowest AIC values were obtained by those listed on the 1 st line of each category in Table 2 . LVEF at 6 months after AMI was best predicted by the LVEF on the 1 st day of AMI, and the size of the perfusion defect at 1 week after AMI. Although we analyzed a possible relationship between the time from onset to reperfusion and the parameters 6 months after AMI or salvaged perfusion DS, there was no significant relationship (data not shown).
Influence of Pharmaceutical Treatments
There was no significant relationship between each pharmaceutical and the incidence of coronary restenosis (data not shown), or between each pharmaceutical and cardiac parameters at 6 months after AMI (perfusion DS, LV volume indices, LVEF, peak-filling rates) [eg, LVEDVI (ml/m 2 ); 93±7 (on angiotensin-converting enzyme (ACE) inhibitor or angiotensin II receptor blocker (ARB)) vs 93±10 (off), p=0.98: LVEF (%); 50±3 (on ACE inhibitor or ARB) vs 51±3 (off), p=0.82].
Influence of Coronary Restenosis
In the 5 patients with coronary restenosis at 6 months after AMI, the AMI site was a proximal portion of the left anterior descending artery. These 5 patients had a larger perfusion defect (p<0.05) with the following data: 56±2, 43±6, 35±3%*, on the 1 st day of AMI and at 1 week and 6 months after AMI, respectively (p<0.05), and larger (p< 
Discussion
Prediction of LV Volumes and Function 6 Months
After AMI Each of LVESVI in the acute phase 2 and the scintigraphic perfusion DS in the subacute phase 3,4 of AMI has been reported to have predictive value for LV dysfunction and remodeling and/or prognosis in the remote phase after AMI. In the present study, LV volumes on the 1 st day after AMI or the perfusion DS at 1 week after AMI contributed to a prediction of the LV volumes 6 months after AMI (Table 2 ). In addition, the combination of such LV volumes and the perfusion DS contributed to a better prediction (much higher R *2 and lower AIC values, Table 2 ) for LVEDVI and LVESVI at 6 months after AMI, and LVEF did for the LVEF at 6 months after AMI. Thus, serial MPI with a QGS analysis provided characteristically higher predictive values of remote LV volumes and functions than those obtained by volumetry or MPI at a given time point during the early post-AMI phase.
The area at risk on the 1 st day of AMI was not a significant parameter for predicting remote LV volumes and functions, apparently because 10±1% of the total LV area (27±3% of the area at risk) was salvaged 1 week after AMI by TIMI grade III reperfusion.
In the classic concept of "LV remodeling", LV volumes may increase and LVEF may decrease after AMI in cases of incomplete reperfusion. In contrast to that concept, complete reperfusion as performed in the present study may reverse the once-dilated LV, leading to LV volume reduction (reverse LV remodeling) and an increase in LVEF at 6 months after AMI. Thus, the patients with TIMI grade III reperfusion by PCI who are found to have large LV volumes and/or low LVEF at 6 months after AMI may have already had much larger LV volumes and/or low LVEF at the onset of AMI. However, in a future study it will be necessary to clarify whether and how such large initial LV volumes and/or low LVEF are induced solely by AMI, or whether they may have existed before the onset of AMI.
LV Diastolic Function After AMI
Although the LV systolic function improved (LVEF: 44± 3% on the 1 st day to 50±2% 6 months after AMI, p<0.05), the peak-filling rate did not change from immediately following reperfusion to 6 months after AMI (Fig 4) , which suggest residual LV diastolic dysfunction 12 in patients with mild to moderate systolic dysfunction at 6 months after AMI. It is necessary to evaluate whether LV diastolic dysfunction improves in the long-term period.
Influence of Coronary Restenosis on LV Remodeling
The 5 patients with coronary restenosis had a greater area at risk, and larger perfusion defect at 1 week after AMI, than the other 43 patients without coronary restenosis, possibly leading to larger LV volumes and lower LVEF. However, the trend of gradual reduction in the LV volumes in these 5 patients was similar to that in all 48 patients and also in the 43 patients without coronary restenosis. This relatively smaller effect on LV volumes may be because the coronary restenosis was not severe at rest.
Influence of Pharmacotherapy on LV Remodeling
The effects of pharmaceuticals on LV remodeling, especially ACE inhibitors or ARB for heart failure, were not apparent in this study for several reasons. First, the number of patients and the observation period may have been insufficient to see the effects of pharmacotherapy. Second, in most previous reports the effects of pharmacotherapy were not necessarily assessed in the presence of TIMI grade III reperfusion. 13 TIMI grade III reperfusion in the present study may have overwhelmed the effects of pharmacotherapy expected in a lower grade of TIMI reperfusion. Third, MPI allowed us to assess 1 aspect of myocardial morbidity after AMI with successful PCI. Other kinds of assessment tools, such as apoptosis imaging 14 or adrenergic nerve imaging, 15 may be helpful in further assessment of myocardial impairment to clarify the effects of pharmacotherapy.
Merits and Demerits of Serial MPI
The merits/demerits of our serial MPI from the standpoint of medical costs and radiation burden inevitably need to be assessed in a future study. The standard medical costs of treatment in a patient with heart failure combined with ischemic heart disease may be approximately $2,800 every year. 16 The addition of MPI just after reperfusion may increase the medical costs by approximately $800, but enable prediction of the patients at high risk of heart failure 6 months after AMI. Then, early introduction of intensive anti-heart failure therapies in such selected patients may result in an annual reduction of medical costs.
It needs to be determined by long-term follow up of the present patients whether the additional radiation burden of repeated MPI affects their health in the future. If the patients show large LV volumes and/or low LVEF at 6 months after AMI, cardiac catheterization may be performed in consideration of possible new development of coronary artery disease. Because the radiation burden of MPI is less than that of cineangiography, serial MPI may contribute to avoiding unnecessary cardiac catheterization.
Clinical Implications
Our results showed that information obtained by serial MPI with QGS analysis just after reperfusion and at 1 week after AMI contributes to predicting remote LV volumes and functions after AMI with TIMI grade III reperfusion. In particular, patients with large LV volumes and/or low LVEF just after reperfusion may still show large LV volumes and/or low LVEF in the remote phase. In addition, such "all-in-one" data acquisition by a single modality may provide a more practical benefit than the multiple-modality methods, such as the combination of left ventriculography, contrast echocardiography and MPI.
Study Limitations
First, the number of patients enrolled was small, and we need a longer follow-up in order to predict patients' prognoses. Second, although patients who needed respirators were excluded because of the difficulty in performing MPI, such patients may indeed be among those who develop remote LV remodeling because of severe heart failure. Third, the main pharmacotherapy in the present study was long-acting nitrates. Our use of -blockers or ACE inhibitors/ ARBs in the patient population appeared to be low compared with other reports on the treatment of AMI. Fourth, we did not examine changes in biochemical markers, such as brain natriuretic peptide. Fifth, because the rate of coronary restenosis in our study seemed to be lower than the usual values in acute AMI, its influence on remote LV remodeling may not be precisely assessed. Sixth, we could not follow the patients in the long-term period, so the reduction of medical costs by early introduction of intensive anti-heart failure therapy remains unclear based on this study.
Conclusion
In the present patients with AMI who obtained TIMI grade III reperfusion by PCI, late reperfusion at approximately 7 h saved 27% of the area at risk, and reverse LV remodeling commonly appeared. Large LV volumes and/or low LVEF at 6 months after AMI appear to be the traces of correspondingly much larger LV volumes and/or low LVEF just after reperfusion. In such a situation, extra effort to perform gated SPECT at the time of reperfusion, in addition to assessment of the perfusion DS at 1 week after AMI, will further help better predict LV volumes and LVEF at 6 months after AMI, although a cost -benefit analysis needs to be assessed in a future study.
